The offering is dilutive and may pressure the stock in the near term due to increased supply. However, the strong pipeline catalyst (positive Phase 1 data and FDA alignment) could provide a floor. Traders should watch for the stock to trade around the offering price of $37.50; a break below that level could signal weakness. Post-lockup expiry (60 days), additional selling from the $200 million ATM facility may add further pressure.
Price Chart
Executive Summary
Enliven Therapeutics filed a 424B5 prospectus supplement for a follow-on public offering of 8,933,334 shares of common stock and pre-funded warrants to purchase 1,733,333 shares at $37.50 per share, raising approximately $400 million in gross proceeds ($376 million net). The offering represents ~17.5% dilution to existing shareholders. Net proceeds will fund R&D for ELVN-001 and general corporate purposes, extending cash runway into 2030. The filing follows positive Phase 1 data and a successful End-of-Phase 1 meeting with the FDA, but the dilutive offering is a certain present event that outweighs the pipeline progress.
Key Facts
- Offering of 8,933,334 shares of common stock and 1,733,333 pre-funded warrants at $37.50 per share (warrants at $37.499).
- Gross proceeds of approximately $400 million; net proceeds of approximately $376 million (or $432.4 million if underwriters' option is exercised in full).
- Underwriters granted a 30-day option to purchase up to an additional 1,600,000 shares.
- Net tangible book value per share will increase from $7.45 to $11.59, resulting in immediate dilution of $25.91 per share to new investors.
- Proceeds will fund ongoing R&D for ELVN-001, including the planned Phase 3 ENABLE-2 trial, and commercial readiness activities.
- Company believes net proceeds plus existing cash will fund operations into 2030.
- Lock-up agreements restrict insider sales for 60 days after the offering date.
Financial Impact
Dilution of ~17.5% based on 10.67 million new shares (including pre-funded warrants) relative to 60.89 million shares outstanding pre-offering. Net proceeds of $376 million increase cash position but dilute existing shareholders.
Risk Factors
- Immediate and substantial dilution of 17.5% to existing shareholders.
- Potential for further dilution from the $200 million ATM sales agreement and exercise of outstanding options/warrants.
- The stock may trade down to or below the offering price as the market absorbs the new shares.
- Clinical-stage biotech risk: ELVN-001 Phase 3 trial may fail or be delayed, reducing the value of the cash raised.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 424B5 Filing (Primary) | 0001193125-26-269621 |
| Document: d114232dexfilingfees.htm | 0001193125-26-269621 |
| Document: 0001193125-26-269621-index-headers.html | 0001193125-26-269621 |
| Document: 0001193125-26-269621-index.html | 0001193125-26-269621 |
| Document: 0001193125-26-269621.txt | 0001193125-26-269621 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 27, 2026 today | SC 13G/A | $41.80 | awaiting T+5 | — | $43.69 (+4.52%) |
Oct 21, 2026 6d ago | Insider Cluster | $41.93 | awaiting T+5 | — | $43.69 (+4.20%) |
Oct 19, 2026 8d ago | 144 | $41.25 $43.69 | ▲ +5.92% | ▲ +5.84% | $43.69 (+5.92%) |
Oct 16, 2026 11d ago | 3 | $38.70 $41.49 | ▲ +7.21% | ▲ +7.35% | $43.69 (+12.89%) |
Oct 14, 2026 13d ago | 8-K | $39.33 $41.93 | ▲ +6.61% | ▲ +7.63% | $43.69 (+11.09%) |
Sep 21, 2026 5w ago | Insider Cluster | $48.19 $46.51 | ▼ −3.49% | ▼ −2.30% | $43.69 (−9.34%) |
Sep 4, 2026 7w ago | 144 | $59.32 $54.43 | ▼ −8.24% | ▼ −7.03% | $43.69 (−26.35%) |
Aug 19, 2026 9w ago | Insider Cluster | $58.97 $60.50 | ▲ +2.59% | ▲ +1.48% | $43.69 (−25.91%) |
Aug 9, 2026 11w ago | Institutional Cluster | $59.42 $59.54 | ▲ +0.19% | ▲ +0.24% | $43.69 (−26.47%) |
Jul 21, 2026 14w ago | Insider Cluster | $52.85 $52.97 | ▲ +0.23% | ▲ +2.63% | $43.69 (−17.33%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers